YOLFTbeta
Enlivex Therapeutics Ltd

Enlivex Therapeutics Ltd

ENLV · NASDAQ · Healthcare / Biotechnology

1.19USD-0.06 (-4.42%)

Price History

Full chart

Market Stats

Previous Close1.25
Open1.30
Day Range1.18 – 1.31
52-Week Range0.57 – 19.80
Volume22.31K
Market Cap10.45M
P/E (TTM)0.00
Forward P/E0.00
EPS381.26
Dividend Yield0.00%
Beta1.42
50-Day Avg1.93
200-Day Avg10.34

About

Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in Ness Ziona, Israel.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Oren Hershkovitz Ph.D.
  • Employees34
  • Headquarters14 Einstein Street, Ness Ziona, Israel, 7403618, USA
  • Websitehttps://www.enlivex.com

Leadership

  • Mr. Shai Novik M.B.A.Executive Chairman · b. 1966
  • Dr. Oren Hershkovitz Ph.D.Chief Executive Officer · b. 1977
  • Prof. Dror Mevorach M.D.Founder & Scientific Advisor · b. 1956
  • Ms. Shachar Shlosberger CPAChief Financial Officer · b. 1977
  • Dr. Veronique Amor-BaroukhChief Operating Officer
  • Ms. Sigal AradDirector of Human Resources
  • Dr. Einat Galamidi M.D.Chief Medical Officer · b. 1974

Financials

Income Statement

Currency: USD2000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue3.58M14.01M18.14M13.53M14.53M25.30M17.18M18.73M----00002.28M00000
Growth (%)-+291.28%+29.49%-25.41%+7.41%+74.07%-32.10%+9.05%----------100.00%----
Cost of Revenue59.57M41.38M3.94M5.87M3.26M7.15M6.43M8.81M--5.00K17.00K25.00K12.00K121.00K297.00K286.00K546.00K777.00K835.00K545.00K332.00K
Gross Profit--14.20M7.66M11.28M18.14M10.75M9.92M---5.00K-17.00K-25.00K-12.00K-121.00K-297.00K-286.00K-546.00K-777.00K-835.00K-545.00K-332.00K
Gross Margin--78.28%56.59%77.59%71.73%62.57%52.95%---------12.56%-----
Operating Expense----------7.08M15.46M13.92M5.84M5.18M8.32M9.50M18.74M25.02M28.56M14.99M14.67M
Operating Income---------226.00K-1.15M-7.08M-15.48M-13.95M-5.85M-5.30M-8.62M-9.79M-19.29M-25.80M-29.39M-15.54M-15.00M
Operating Margin-----------------429.73%-----
EBITDA---------226.00K-1.14M-7.08M-15.31M-15.78M-5.91M-5.18M-8.41M-9.50M-18.74M-25.02M-28.22M-14.47M-14.67M
EBITDA Margin-----------------417.17%-----
Net Income---------229.00K-1.15M-7.02M-15.37M-16.02M-5.95M-4.24M-9.38M-11.82M-14.47M-31.06M-29.07M-15.01M1.24B
Net Income Margin-----------------519.28%-----
R&D7.25M9.55M5.55M4.21M3.43M4.48M3.92M3.27M140.00K732.00K4.44M7.69M8.88M2.52M4.13M5.72M6.09M12.88M18.69M19.23M10.13M8.92M
R&D as % of Total Revenue202.40%68.20%30.59%31.11%23.62%17.71%22.82%17.43%--------267.28%-----
Interest Expense0000000002.00K6.00K12.00K003.00K7.00K6.00K328.00K5.26M14.00K13.00K13.00K
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%--------0.26%-----

Balance Sheet

Currency: USD2000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets102.40M61.92M53.35M45.74M45.27M45.14M27.69M42.20M156.00K5.69M32.95M20.52M10.63M3.62M11.03M17.56M40.36M95.15M67.64M36.83M27.69M2.33B
Total Liabilities6.06M9.18M14.71M18.17M10.03M9.27M7.53M14.11M81.00K131.00K2.28M2.58M1.93M460.00K1.33M6.28M4.87M10.11M10.80M6.75M4.10M392.05M
Total Equity96.34M52.74M38.64M27.58M35.24M35.86M20.16M28.09M75.00K5.55M30.67M17.93M8.70M3.16M9.71M11.28M35.49M85.04M56.84M30.08M23.59M1.93B
Cash13.32M8.35M10.68M8.53M5.96M6.44M4.15M6.93M146.00K5.55M10.58M7.29M6.87M3.53M9.74M3.95M5.67M11.20M49.95M813.00K3.30M2.01M
Total Debt---------------123.00K203.00K6.01M4.85M1.03M534.00K641.00K
Net Debt---------146.00K-5.55M-10.58M-7.29M-6.87M-3.53M-9.74M-3.83M-5.47M-5.20M-45.10M219.00K-2.77M-1.37M

Cash Flow

Currency: USD2000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow---------149.00K-865.00K-4.41M-13.25M-15.49M-6.35M-3.16M-7.04M-11.01M-17.54M-23.95M-23.52M-13.01M-10.42M
Investing Cash Flow1.58M8.39M5.14M13.00K--1.89M---2.00K-22.06M9.95M8.98M3.01M-533.00K-6.36M-20.98M-38.41M62.52M-25.97M9.06M-1.32M
Financing Cash Flow35.99M1.87M7.53M1.97M9.24M7.25M1.63M15.36M295.00K991.00K36.78M36.78M6.09M8.05M5.19M8.31M33.08M60.98M150.00K360.00K6.45M10.38M
Capital Expenditure4.23M872.00K936.00K461.00K418.00K389.00K450.00K664.00K02.00K63.00K48.00K18.00K2.00K461.00K193.00K1.02M1.63M8.12M236.00K103.00K68.00K
Free Cash Flow---------149.00K-867.00K-4.47M-13.30M-15.50M-6.35M-3.62M-7.23M-12.03M-19.17M-32.08M-23.76M-13.11M-10.48M
FCF to OCF--------100.00%100.23%101.43%100.36%100.12%100.03%114.58%102.74%109.26%109.26%133.91%101.00%100.79%100.65%

Earnings

Report DateAug 29, 2014Nov 21, 2014Feb 17, 2015May 19, 2015Aug 21, 2015Nov 17, 2015Feb 23, 2016May 25, 2016Aug 25, 2016Nov 29, 2016Feb 24, 2017May 26, 2017Aug 4, 2017Nov 2, 2017Feb 23, 2018Apr 23, 2018Aug 24, 2018Dec 31, 2018Mar 27, 2019May 20, 2019Jul 26, 2019Nov 14, 2019Feb 21, 2020May 18, 2020Aug 14, 2020Oct 30, 2020Feb 26, 2021May 28, 2021Aug 6, 2021Nov 19, 2021May 27, 2022Aug 22, 2022Dec 2, 2022Mar 31, 2023Jun 16, 2023Jul 31, 2023Nov 9, 2023Mar 29, 2024Jun 14, 2024Aug 30, 2024Nov 29, 2024Mar 31, 2025May 30, 2025Aug 29, 2025Nov 14, 2025Mar 25, 2026Jun 26, 2026Sep 25, 2026
EPS Estimate--3.40-6.20-9.80-11.20-11.60-10.00-11.40-10.80-8.80-10.80-11.60---0.000.000.000.00----0.25-3.60-3.60-2.70-0.24-3.15-3.90-3.15-6.15-6.75-4.35-5.70-6.00-0.46-4.80-4.20-3.75-1.20-2.40-0.16-2.40-2.40-1.80-0.45-0.02-0.31
EPS Actual-4.04-6.40-8.80-9.20-10.40-9.20-13.60-12.80-8.80-11.20-7.60-6.40-4.00-2.56-0.16-2.34-0.50-0.12-0.16-0.16-0.16-0.24-0.25-1.05-3.45-2.40-0.25-2.85-2.55-2.85-6.75-8.10-4.65-5.85-5.85-0.40-4.80-7.20-3.30-2.40-1.80-0.23-2.25-1.20-1.35-1.41-0.15-1.20
Surprise--88.24%-41.94%6.12%7.14%20.69%-36.00%-12.28%18.52%-27.27%29.63%44.83%----------0.00%70.83%4.17%11.11%-4.17%9.52%34.62%9.52%-9.76%-20.00%-6.90%-2.63%2.50%13.04%0.00%-71.43%12.00%-100.00%25.00%-43.75%6.25%50.00%25.00%-213.33%-650.00%-287.10%
TimingAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-market-After-hours-Pre-marketAfter-hoursPre-marketPre-marketAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursPre-market--

Key Statistics & Ratios

Market Cap10.45M
Enterprise Value6.20M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book0.01
EPS381.26
Book Value122.27
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-14.67M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity126.17%
Return on Assets-0.80%
Shares Outstanding17.49M
Shares Float4.82M
Beta1.42
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 2 analystsTarget 80.00
  • Strong Buy
    1
  • Buy
    1

Ownership Breakdown

Institutions
1.62%
Insiders
78.36%
Retail / Other
20.02%

Top Institutional Holders

  • Diametric Capital, LP
    1.48M0.57%
  • ARK Investment Management LLC
    628.31K0.24%
  • Springbok Capital Management, LLC
    225.74K0.09%
  • Two Sigma Investments LLC
    183.92K0.07%
  • UBS Group AG
    138.33K0.05%
  • Bank of America Corp
    130.40K0.05%
  • Renaissance Technologies Corp
    128.19K0.05%
  • JPMorgan Chase & Co
    125.95K0.05%
  • The Goldman Sachs Group Inc
    102.09K0.04%
  • XTX Topco Ltd
    100.36K0.04%
  • Morgan Stanley - Brokerage Accounts
    98.33K0.04%
  • Geode Capital Management, LLC
    80.56K0.03%
  • Amvescap Plc.
    61.65K0.02%
  • Virtu Financial LLC
    43.25K0.02%
  • TWO SIGMA SECURITIES, LLC
    20.04K0.01%
  • Prosperity Consulting Group, LLC
    17.65K0.01%
  • Neuberger Berman Group LLC
    10.99K0.00%
  • Susquehanna International Group, LLP
    10.31K0.00%
  • SkyView Investment Advisors, LLC
    10.00K0.00%

Top Fund Holders

  • Fidelity Nasdaq Composite Index
    8.66K0.05%

Stock Splits

  • Oct 27, 20261:16
  • Jul 9, 20261:15
  • Mar 6, 20191:8
  • Sep 25, 20171:5